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Abstract Inflammation is increasingly recognized as a con-
tributor to the pathophysiology of neuropsychiatric disorders,
including depression, anxiety disorders and autism, though the
factors leading to contextually inappropriate or sustained in-
flammation in pathological conditions are yet to be elucidated.
Microglia, as the key mediators of inflammation in the CNS,
serve as likely candidates in initiating pathological inflamma-
tion and as an ideal point of therapeutic intervention. Glucose
deprivation, as a component of the pathophysiology of ische-
mia or occurring transiently in diabetes, may serve to modify
microglial function contributing to inflammatory injury. To this
end, primary microglia were cultured from postnatal rat brain
and subject to glucose deprivation in vitro. Microglia were
characterized for their proliferation, phagocytic function and
secretion of inflammatory factors, and tested for their capacity
to respond to a potent inflammatory stimulus. In the absence of
glucose, microglia remained capable of proliferation, phagocy-
tosis and inflammatory activation and showed increased release
of inflammatory factors after presentation of an inflammatory
stimulus. Glucose-deprived microglia demonstrated increased
phagocytic activity and decreased accumulation of lipids in
lipid droplets over a 48-h timecourse, suggesting they may
use scavenged lipids as a key alternate energy source during
metabolic stress. In the present manuscript, we present novel
findings that glucose deprivation may sensitize microglial re-
lease of inflammatory mediators and prime microglial func-
tions for both survival and inflammatory roles, which may
contribute to psychiatric comorbidities of ischemia, diabetes
and/or metabolic disorder.
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Introduction
Inflammation of the central nervous system, regulated by mi-
croglia—the resident immune cells, is an acute reaction to the
presence of infectious agents, foreign bodies or tissue damage
intended to protect, contain and repair vulnerable CNS tissues.
In an increasing number of neuropathologies, prolonged, in-
appropriate or chronic inflammation has been shown to exac-
erbate damage to surrounding neural and glial cells.
Inflammation is implicated in the development of numerous
neurodegenerative disorders, including Alzheimer’s [1, 2],
Parkinson’s [3, 4] and Huntington’s diseases [5], acute condi-
tions including ischemic and hemorrhagic stroke [6–9], trau-
matic brain injury [10–12] and spinal cord injury [13] and
neuropsychiatric disorders including depression and anxiety
disorders [14–16], schizophrenia [17–20], autism [21–24] and
post-traumatic stress disorder [25, 26]. While recent studies
have shed light on both the importance of microglia-mediated
inflammation in normal repair processes and the evidence for
pathological inflammation in neuropsychiatric disorders,
much remains unknown about the mechanisms and triggers
involved in normal and pathological inflammation, and the
divergent functions of microglia in carrying out both trophic
and toxic roles in the CNS.
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Inflammation as a component of psychiatric disorders has a
number of possible sources. A recently popularized hypothesis
postulates the aetiology of depression may derive, in part, from
prolonged or chronic immune activation [15, 27, 28].
Consistent with this hypothesis, a number of studies have found
elevated peripheral cytokines (particularly tumour necrosis fac-
tor (TNF) and interleukin-6 (IL-6)) in depressed patients, and
depression is the most observed psychiatric comorbidity of
medical illness [29]. Rates of depression are elevated in a wide
range of medical conditions including coronary heart disease,
cancer, diabetes, ischemic stroke and in particular chronic in-
flammatory diseases (autoimmune disorders, rheumatoid arthri-
tis, inflammatory bowel disease, asthma and allergies) [28,
30–34]. While many have argued that comorbid depression is
expected as a consequence of ‘feeling bad’ about having a
chronic illness, comorbid depression paradoxically does not
necessarily correlate with disease prognosis (e.g. in cancers
with positive expected outcome) nor with disease severity
(e.g. in the case of asthma and allergies, which are both man-
ageable and can have limited impact on daily life) [27]. An
alternate explanation of comorbid depression is that clinical
depression is difficult to distinguish from sickness behaviours,
i.e. depressed mood, anhedonia, social withdrawal, appetite
changes and fatigue as an adaptive phenotype to prioritize re-
covery from infection or illness [35, 36]. Supporting this argu-
ment is the observation that sterile inflammation, through ad-
ministration of either cytokines (interferon-α (IFN-α) or IL-2 as
immune boosters for hepatitis C or cancer treatments) or bacte-
rial lipopolysaccharide (LPS), results in manifestation of de-
pressive symptoms [37–39]. By extension, observed increases
in inflammatory markers in otherwise medically healthy de-
pressed patients suggests depression, in some cases, may result
from maladaptive expression of sickness behaviours in the ab-
sence of infection or illness. Such observations in psychiatric
and neurological disease has led to recent understanding that
inflammation is a key component of the pathophysiology of
many neurological, neurodegenerative and neuropsychiatric
disorders, and is encouraging research into the mechanisms
underlying inflammatory processes in the CNS [18].
The desire to understand inflammatory processes in the
CNS necessitates an understanding of microglia. Microglia
are functionally unique in the CNS, and are distinguished in
part by their persistent function in environments that are ad-
verse to the survival of neurons and other glial cells. This in-
cludes relatively minor disruptions of homeostasis, such as al-
terations in extracellular pH and nutrient levels, to extremely
adverse environments such as the core of an ischemic injury
[40]. Such an environment is devoid of blood flow, and hence
subject to deprivation of oxygen, glucose and other nutrients,
accompanied by loss of neurons, astrocytes, oligodendrocytes
and other resident cells, yet microglia survive, proliferate and
migrate to the ischemic infarct [41–44]. Inflammation as a con-
sequence of ischemia has been best studies in models of
ischemic stroke, though may significantly contribute to the
pathogenesis of neurodegenerative and neuropsychiatric dis-
ease. Depression is the most common psychiatric comorbidity
following ischemic stroke, and has a significant effect on re-
covery and prognosis [45], while some have proposed that
depression, particularly in ageing patients, may result from
subcortical ischemia due to vascular insufficiency [46, 47]. In
a similar fashion, age-related cognitive impairment and demen-
tia is a well-documented consequence of mild or chronic ische-
mia [48–51], and some have proposed dementia associated
with Alzheimer’s may result in part from local hypoxic/
ischemic conditions [52–54]. Transient glucose deprivation in
the absence of hypoxia can occur in diabetes, particularly in
patients with insulin resistance, and is considered a major clin-
ical concern in diabetes management [55]. Type II diabetes has
a well-characterized bidirectional association with depression:
patients with type II diabetes are at an increased risk of depres-
sion, and patients with depression are at an increased risk of
developing type II diabetes (reviewed by Berge and Riise [56]).
Several mechanisms have been proposed to explain the rela-
tionship between depression and diabetes including the influ-
ence of shared lifestyle and socioeconomic risk factors, con-
verging effects of cytokines and cortisol on both insulin resis-
tance and CNS inflammation and the contribution of advanced
glycation end-products to inflammatory processes and subse-
quent effects on cognitive function [56–59]. Imaging work has
demonstrated a relationship between a history of severe hypo-
glycemic events and decreased grey matter density in patients
with type I diabetes [60], raising the intriguing possibility that
variation in glucose levels, persistent hyperglycemia and tran-
sient hypoglycemia, may each contribute to neuropathology,
cognitive impairment and psychiatric comorbidities in diabetes.
Consequently, an improved understanding of the effects of glu-
cose deprivation on the function of microglia will provide in-
sight into mechanisms underlying neuroinflammation as relates
to neuropsychiatric and neurodegenerative disease, particularly
comorbid depression and diabetes.
Much of our understanding of the role of microglia in inflam-
mation comes by analogy to the role of macrophages in periph-
eral inflammation. Indeed, given the relative challenge and ex-
pense of either fresh isolating or culturing primary microglia
from human tissues, isolation of monocytes and their polariza-
tion into macrophages has remained one of the few viable reduc-
tionist systems formechanistic studies of inflammation in human
cells. Animal studies have demonstrated remarkable differences
exist between the form and function of macrophages and mi-
croglia, particularly as relates to CNS homeostasis and repair.
While both cell types can be involved in CNS inflammation
and restoration of homeostasis, they behave very differently
[61]. Microglia respond to a variety of factors by taking on a
pro-inflammatory state that both morphologically and function-
ally resembles a macrophage, engaging in phagocytosis of cel-
lular debris and secretion of pro-inflammatory factors such as
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cytokines (IL6, IL1β, and TNF), chemokines (chemokine (C-C
motif) ligand 3, 5 (CCL3, CCL5)) and reactive oxygen/nitrogen
species (nitric oxide, peroxides, superoxide, peroxynitrite) to
regulate the fate of pathogens and vulnerable neurons; however,
aside from this specific state, the similarities are greatly dimin-
ished [62–65]. Microglial activation is a misnomer that is unfor-
tunately widely propagated in the literature—microglia are con-
stitutively active across a continuum of states leading to expres-
sion of a wide variety of cellular behaviours [66, 67]. In the
surveillant or homeostatic state in healthy CNS tissue, microglia
are highly active, extending and modifying their branched arbor-
izations to physically sample the entire volume of the CNS ap-
proximately every 2 h [68–71]. These microglia are territorial:
two adjacent microglia will maintain respectful boundaries in
order to prevent redundant oversampling of the parenchyma. In
response to internal or external stimuli, microglia enter a reactive
state and are capable of secreting a wide variety of substances to
modify the function of surrounding cells. This includes factors
such as are described for ‘classical’ and ‘alternate’ activation of
macrophages to the M1 and M2 phenotypes, respectively; how-
ever, these are far from discrete states in microglial popula-
tions—these represent a snapshot of activity along a functional
continuum, and in fact microglia have been demonstrated to
simultaneously express both M1 and M2 markers [67, 72]. In
further contrast to macrophages—thought to polarize towards
either secretory or phagocytic phenotypes, microglia are highly
capable of phagocytosis across their functional continuum, in-
cluding specific developmental and plasticity-related roles in
activity-dependent synaptic pruning and phagocytic regulation
of neuronal precursor cell populations which occur in the ab-
sence of overt inflammatory conditions [73–75]. Microglia and
macrophages vary in their response to CNS injury—recent work
has shown that macrophages, whether polarized to the inflam-
matory M1 phenotype or the ‘trophic’ M2 phenotype, are inju-
rious to neurons in an ex vivo model of ischemic injury, while
microglia are uniquely capable of protecting and promoting re-
covery of vulnerable neurons [76]. Further, as a resident popu-
lation, microglia are self-sustaining: both microglia and macro-
phages proliferate in response to inflammatory stimuli; however,
macrophages have a terminal endpoint after resolution of inflam-
mation while microglia are capable of returning to a surveillant
state to restore the homeostatic population [77, 78]. These studies
demonstrate the need for direct investigations into the specific
roles of microglia in the initiation, propagation and resolution of
inflammation in the CNS.
Ischemia is generally modelled in vitro using oxygen and
glucose deprivation (OGD), mimicking two of the key insults
to occur during ischemia. In either ex vivo slice culture prepa-
rations or isolated in vitro cultures, microglia respond to OGD
by increasing secretion of both pro-inflammatory cytokines and
trophic growth factors [76, 79–81]. This release highlights one
of the therapeutic challenges of targeting inflammation: mi-
croglia are both essential for repair and to limit spread of
ischemic injury, and contributors to secondary damage in is-
chemic tissue [82–84]. The effects of hypoxia on microglia are
well documented: activation of hypoxia-inducible factor-1α
(HIF1α) leads to transcription of numerous genes, including
expression of pro-inflammatory cytokines [85–87]. HIF-1α is
also responsible for alteration of glycolytic pathways to favour
anaerobic metabolism [88] to prevent energy failure and pro-
mote cell survival. Recent work has suggested that hypoxia and
glucose deprivation may have antagonistic effects on release of
inflammatory cytokines [89], which may also contribute to
conflicting reports in the literature regarding the survival of
microglia after OGD [80, 90, 91].
Interestingly, very few reports have sought to determine the
direct effects of glucose deprivation (GD) onmicroglial function.
In a recent study, Choi and colleagues reported that glucose
deprivation increased gene expression and secretion of the cyto-
kine Il-6 from both immortalized microglial cell lines and prima-
rymurinemicroglia in vitro, and these changeswere antagonized
by coincident application of hypoxia [89]. While these specific
findings suggest GD, but not hypoxia, increased inflammatory
release, it is important to note that effects on a single cytokine
cannot be generalized to an overall effect on release of inflam-
matory mediators, particularly as hypoxia is a well-identified
activator of inflammation both in vitro and in vivo [85–87].
Given the correlation between ischemia/hypoglycemia and psy-
chiatric disorders (notably depression) and lack of available ev-
idence, we proposed the following question:what effect does the
availability of glucose have on the initiation of inflammation in
theCNS?As pro-inflammatory functions ofmicroglia are energy
intensive, requiring new protein synthesis and extensive cyto-
skeletal reorganization, it is perhaps unsurprising that treatment
with inflammatory stimuli such as LPS and IFN-γ results in
increased glucose uptake and utilization [92, 93] and result in
distinct metabolic changes to support such vital functions [94].
Given these energy demands, and previous work suggesting
antagonistic effects of hypoxia and hypoglycemia, we proposed
the following specific hypothesis: glucose deprivation will ren-
der microglia less capable of releasing inflammatory modulators
when presented with an exogenous inflammatory stimulus. As
an initial test of this hypothesis, we determined the effects of GD
on primary cultured microglia, and found that contrary to our
hypothesis glucose-deprived microglia showed comparable or
increased capacity for phagocytic and inflammatory function.
Methods
Materials
DMEM/Ham’s F-12 (DMEM/F-12, 1:1), foetal bovine serum
(FBS), penicillin/streptomycin, 0.25% trypsin/EDTA and
Hank’s balanced saline solution (HBSS) were from Gibco
(Thermo-Fisher Scientific, Ottawa, ON). Bodipy 493/503
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and Click-IT EdU Imaging kit were from Molecular Probes
(Thermo-Fisher Scientific, Ottawa, ON). ELISA kits for IL1β
and TNF were from R&D Systems (Minneapolis, MN, USA).
All other reagents were of the highest quality available.
Primary Microglial Cell Culture and Treatments
Microglia were isolated from mixed glial cultures at 14 days
in vitro (d.i.v.) according to the method of Saura [95]. Whole
brains were isolated from male postnatal day 1 rat pups, me-
ninges removed and single cell suspensions generated by
trypsinization and trituration. Mixed glial cultures were main-
tained on 12-well plates with DMEM/F-12, 10% FBS, 200 U/
ml penicillin, 200 μg/ml streptomycin in a 37 °C, 5% CO2
humidified incubator for 14 days and isolated by mild
trypsinization (0.25% trypsin/EDTA diluted to 30% strength
with DMEM/F12). Isolated cultures were consistently of
≥98% purity in all conditions and experiments, and were
maintained in DMEM/F12 with 1% FBS for 18 h prior to start
of experiments. All animal procedures were performed in ac-
cordance with the University of Alberta animal care and use
committee’s regulations.
For glucose deprivation treatments, microglia were first
washed thoroughly with fresh glucose-free DMEM/F-12 or
17.5 mM glucose DMEM/F-12 as appropriate and maintained
with glucose-free or 17.5 mM glucose containing 1% FBS
without antibiotics for 1 or 24 h prior to LPS treatment
(100 ng/ml for 24 h in both 24- and 48-h treatments as outlined
in Fig. 1a) and through the course of the experiment.
Molecular Analyses
Nitric oxide levels were estimated by measuring the major
metabolite nitrite using the Griess reaction [96, 97]. ELISAs
for TNF and IL1β were performed according to the manufac-
turer’s instructions (R&D Systems, Minneapolis, MN).
All molecular analyses were normalized to the protein level
of the cell lysate, measured using the BCA assay (Thermo-
Fisher Pierce, Ottawa, ON) to account for any variability in
cell numbers between wells.
MTT assay was performed by incubation with 0.5 mg/ml
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) for 30 min, lysis with dimethylsulfoxide and
measurement of the oxidized formazan end-product at
540 nm. MTT results are presented uncorrected for total cell
number but with cell counts determined in a parallel assay
plate within the same experiment.
Microscopy
Proliferation was assessed by incorporation of 5-ethynyl-2′-
deoxyuridine (EdU) according to the manufacturer’s protocol
(Click-IT EdU Imaging kit, Thermo-Fisher Scientific). Lipid
droplets were visualized by staining with Bodipy 493/503
[98]. Phagocytosis was assayed by incubating treated cells
with 1 × 107 green fluorescent 1 μm carboxylate-modified
latex beads (Sigma, Oakville, ON) for 2 h at 37 °C, 5%
CO2, followed by thorough HBSS wash and fixation with
5% phosphate-buffered formalin as previously described
[99]. Images were acquired using a Leica AF6000-LX micro-
scope. Confocal microscopy was performed on a Leica TCS-
SPE inverted microscope to validate bead internalization.
Post-processing and quantitative analysis was performed
using ImageJ using custom written macro functions as previ-
ously described [99]. Cell density measurements were deter-
mined by counting the total number of microglial cells in an
automatically acquired 21-image array covering a total plate
area of 25.5 mm2 for each condition.
Statistical Analyses
Normality was determined using the D’Agostino-Pearson om-
nibus test. Overall significance was assessed using two-way
ANOVA, with Bonferroni’s multiple comparison post-hoc
analysis between groups. Pairwise comparisons were assessed
using a Mann-Whitney U test. A P value of ≤0.05 was con-
sidered significant. Data are presented as the mean ± SEM.
Each reported N indicates an independent experiment from a
separate primary culture preparation.
Results and Discussion
GD was carried out 1 h prior to LPS treatment for a total of
24 h to examine the acute effects of energy deprivation on the
initiation of inflammatory functions [Fig. 1a]. GD of primary
cultured microglia was insufficient to induce release of in-
flammatory modulators (TNF, IL1β or NO) but did signifi-
cantly increase release of NO from reactive microglia after
treatment with 100 ng/ml LPS [Fig. 1B] and showed a trend
towards increased release of IL1β [Fig. 1c]. GD treatment was
extended to 48 h in order to examine the possibility microglia
were maintaining functions by depleting short-term stores of
energy [Fig. 1a]. LPS treatment after 24 h of GD (48 h total
timecourse) resulted in comparable trends towards increased
release of NO, and a significant increase in the release of IL1β
[Fig. 1b–c]. At both time points, TNF release was unaffected
by glucose deprivation [Fig. 1d]. This observed increase of
release suggests GD may result in a sensitization or ‘priming’
of microglial function to facilitate subsequent inflammatory
release, but does not clarify the increased metabolic demand
required to initiate inflammation. Cell metabolic activity, de-
termined by the reduction of the tetrazolium dye 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT), was sig-
nificantly decreased as a consequence of GD treatment in both
the presence and absence of LPS treatment [Fig. 1e], and
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comparable effects were observed after 48 h of GD. As MTT
reduction is dependent on NAD(P)H-dependent oxidoreduc-
tase enzymes, this suggests GD induced metabolic changes
resulting in decreased oxidative phosphorylation and activity
of the pentose phosphate pathway [100, 101]. Notably, these
changes in MTT did not correlate with changes in cell num-
bers—parallel analysis of cell counts showed no significant
difference in cell density as a consequence of glucose depri-
vation [Fig. 1e].
Cell morphology and culture confluence was not affected
by GD treatment as determined by immunofluorescence mi-
croscopy [Fig. 2a–b]. Microglia labelled with the selective
marker ionized Ca2+-binding adaptor protein-1 (Iba1) showed
a variety of morphologies including a typical branched mor-
phology suggestive of the surveillant state in both normal and
glucose-deprived conditions. Notably, glucose-deprived cells
showed a comparable confluence to control conditions and
showed no indications of poor health (spherical morphology,
condensed/fragmented nuclei, nor changes in media pH).
Phagocytic activity of primary microglia was assessed by
measuring the uptake of fluorescent beads as previously de-
scribed [99]. Neither glucose deprivation nor LPS treatment
altered the proportion of cells involved in phagocytosis, re-
maining consistent between 65 and 72% in all conditions
[Fig. 2c]; however, glucose deprivation significantly increased
the uptake of beads. The mean fluorescence of phagocytic
cells (mean fluorescence is proportional to the number of
beads internalized per cell) was significantly higher in the
GD condition relative to the normal glucose control in the
absence of LPS treatment [Fig. 2d]. As expected, LPS
Fig. 1 Glucose deprivation is
insufficient to induce
inflammatory release from
microglia. a Schematic timeline
of treatment paradigm. For each
condition, GD began 1 or 24 h
(for 24 or 48 h total time points,
respectively) prior to 24 h 100 ng/
ml LPS treatment. b–d Release of
NO (b), IL1β (c) and TNF (d) is
significantly increased by
treatment with LPS. GD increases
release of NO and IL1β
significantly above the LPS
treated, normal glucose condition
at 24 and 48 h, respectively
(N = 4). MTTassay (e), a measure
of oxidative phosphorylation, was
significantly decreased in
microglia subject to glucose
deprivation relative to normal
glucose at 24 h, and in the
presence of LPS at 24 or 48 h
(N = 8). Numbers indicate mean
cell density for each condition as
determined from a parallel assay
plate. N.D. not determinable.
Asterisk indicates significant
groupwise differences by two-
way ANOVA between control
and LPS and Double asterisk
indicates pairwise significance by
Bonferroni’s post hoc
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increased the overall intake of beads significantly relative to
the untreated condition, which abrogated the effect of glucose
deprivation. This increased phagocytic activity precedes in-
flammatory activation, and is not accompanied by release of
inflammatory mediators, but may reflect an increase in sur-
veillance activities in response to metabolic stress. Coupled
with the sensitization of inflammatory release observed in GD
microglia, these data suggest GD may cue microglia to alter
their function in anticipation of further insult. In contrast to the
effects of glucose deprivation on inflammatory release and
phagocytosis, GD did not affect either the viability of
microglia (in terms of total cell numbers) or the proliferation
rate in vitro. Proliferation, measured based on the incorpora-
tion of the nucleotide analogue 5-ethynyl-2′-deoxyuridine
(EdU), was not significantly altered under any of the tested
conditions, remaining consistent at ~20% [Fig. 2e].
The survival, proliferation and functional capacity ofmicrog-
lia under glucose deprivation raises the question of alternative
energy sources. In a number of cell types, nutritional depriva-
tion results in mobilization of fatty acids from internal stores,
including lipid droplets [102]. The accumulation of trigycerides
in lipid droplets during nutritional deprivation is accompanied
Fig. 2 Glucose deprivation alters
the function, but not the viability
and proliferation, of microglia.
Experiments were performed as
in Fig. 1a, 24 h total time course.
Immunofluorescence microscopy
did not reveal any morphological
differences between microglia
cultured in normal glucose (a) or
glucose deprived (b) media.
Microglia were labelled with (i)
Hoechst 33342, (ii) Bodipy 493/
503, and (iii) Iba1, arrowheads in
the overlay (iv) indicate microglia
showing detectable lipid droplets
as indicated by Bodipy 493/503
staining. c Phagocytosis as a
portion of cells taking up
fluorescent beads was not
significantly affected by glucose
deprivation (N = 6). d Phagocytic
uptake, in terms of mean uptake
of fluorescent beads per cell, was
significantly increased with
glucose deprivation (N = 6). e
Proliferation, as measured by
incorporation of the nucleotide
analogue EdU, was not
significantly affected by glucose
deprivation (N = 3). Asterisk
indicates groupwise differences
between control and LPS
treatment by two-way ANOVA,
Dagger indicates pairwise
difference between normal
glucose and GD by Mann-
Whitney U test
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by an increase in β-oxidation of fatty acids as a survival mech-
anism, and been observed in a number of immortalized cell lines
as well as rat primary astrocytes in vitro [98, 102, 103]. This
accumulation of lipid droplets has been observed in in vivo
models of ischemic stroke to correlate with CD11b + microg-
lia/macrophages, and is suggested to contribute to a unique
magnetic resonance signal observable in human patients after
ischemic stroke using proton magnetic resonance spectroscopy
[104]. To explore the influence of glucose treatment on lipid
stores, accumulation of lipid droplets was assayed using the
neutral lipid stain Bodipy 493/503. Immunofluorescence mi-
croscopy demonstrated Bodipy 493/503 staining was visible
in a small subset of microglial cells after 24 h treatments
[Fig. 2a–b] and lipid stores were predominantly associated with
the cell soma and typically excluded from extended processes
[Fig. 2a–b, Supplementary Fig. 1] and did not colocalize with
the lysosomal marker CD68 [Supplemental Fig. 1].
Quantitative analysis of Bodipy 493/503 staining indicated lipid
droplet accumulation was not significantly affected by 24 hGD;
however, over the course of 48 h GD treatment, microglia did
not significantly accumulate lipid stores [Fig. 3, Supplementary
Fig. 1c]. This contrasts with the normal glucose condition in
which a significant increase in lipid droplets was observed over
48 h. Both normal and GD microglia showed a significant in-
crease in lipid droplets on challenge with LPS at 24 or 48 h
[Fig. 3, Supplementary Fig. 1b, d], which suggests GDmicrog-
lia are equally capable of reacting to external stimuli. The
observed increase in lipid droplets size and/or number after
exposure to LPS is consistent with observed LPS-induced ac-
cumulation of lipid droplets in the immortalized N9 microglial
cell line [98, 103] andmay be reflective of lipid redistribution as
the cells undergo morphological changes from the branched,
surveillant morphology to a spherical, reactive morphology
rather than de novo synthesis of fatty acid stores. Alternately,
as microglia are phagocytic cells and show significantly in-
creased phagocytic uptake under conditions of glucose depriva-
tion in the absence of LPS stimulus [Fig. 2d], this accumulation
may reflect lipid taken in through phagocytosis of cellular de-
bris. Notably, sustained LPS stimulation typically results in a
high degree of cellular turnover as indicated by reduced cell
density after LPS treatment [Fig. 1e] which may present oppor-
tunities for phagocytic uptake in the remaining cells. This path-
way would provide continuous input to support vital functions
of microglia during conditions of nutritional stress, including
ischemia and would ultimately confound our assessment of
lipid stores. Indeed, the observation that increased phagocytic
activity during glucose deprivation was accompanied by a fail-
ure to further accumulate lipid stores may suggest stores are
being actively depleted during the course of the experiment.
In addition to the potential sustenance of vital function, lipid
droplet accumulation in some cell types is associated with
unfavourable outcomes: accumulation of lipid droplets in pe-
ripheral macrophages results from uptake of oxidized low-
density lipoproteins and ultimately contributes to macrophage
death and deposition in atherosclerotic plaques [105, 106],
while comparable accumulation of lipid droplets in microglia/
infiltrating macrophages during ischemic stroke contributes to
the development of lipid-rich deposits in the core of injury
[107]. It is as yet unclear if microglial accumulation of lipid
droplets contributes to expression of either trophic or toxic be-
haviours in conditions of oxygen and/or glucose deprivation.
Conclusion
The dynamic response ofmicroglia to conditions of nutritional
deprivation stands in contrast to our original hypothesis—we
had expected a decrease in proliferation and a likely decrease
in release of inflammatory mediators from reactive microglia.
Glucose deprivation significantly affected cellular metabo-
lism, as indicated by marked decrease in oxidative phosphor-
ylation; however, rather than adopting a quiescent functional
state, primary microglia increased phagocytic behaviours in
the absence of glucose, and reactive microglia subject to GD
increased the release of inflammatory mediators. This was
notably accompanied by maintenance of the viability and pro-
liferation of microglia. Thus, in the absence of glucose, mi-
croglia maintain or increase essential surveillance functions,
and show sensitization of energy-intensive inflammatory pro-
cesses. This unique aspect of microglial function stands in
Fig. 3 Glucose deprivation alters the accumulation of lipid droplets.
Accumulation of lipid droplets was quantified by staining with
BODIPY 493/503 and integration of green fluorescence within the soma
of microglia identified by Hoechst 33342 and CD68 labelling, and is
indicative of an increased size and/or number of lipid droplets.
Fluorescence was significantly increased over the course of 48 h in the
normal glucose condition, but not during glucose deprivation. Both
normal and glucose-deprived cells showed significant increases in
BODIPY 493/503 staining after LPS stimulation at either 24 or 48 h.
Asterisk indicates significant groupwise differences by two-way
ANOVA between control and LPS and Double asterisk indicates
pairwise significance by Bonferroni’s post hoc (N = 4)
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contrast to cells of the peripheral immune system, which have
been shown to require oxidative phosphorylation and/or gly-
colysis for inflammatory functions—blockade of which re-
sults in a diminished inflammatory response [108–111] (and
reviewed in [112]). While unexpected, these findings may
reinforce the functional distinction between microglia and
their counterparts in the peripheral immune system, and high-
light specialized adaptations of inflammatory processes for
diverse roles in the maintenance of brain homeostasis, devel-
opment and plasticity [113]. It is not surprising that microglia
are capable of utilizing alternate energy sources during glu-
cose deprivation, as redundancy is a common feature of
microglial function [114]. There remain unanswered questions
of what primary energy stores are utilized by microglia during
glucose deprivation, though the mobilization of fatty acids
from internal stores would be expected given such observa-
tions in other cell types [102]. It is worth noting that microglia
in the current study were not subjected to complete nutritional
deprivation, but as glucose is the principal energy source in
the brain it would be expected to be depleted rapidly during an
ischemic or hypoglycemic event. The cell culture media used
in the present study contain significant levels of amino acids
which may be catabolized to intermediates capable of entry
into the tricarboxylic acid cycle to sustain cellular metabolism,
thus limiting the determination of a direct role of lipid stores.
In the event of complete nutritional deprivation, we may ex-
pect a continuation of the observed trend towards sensitiza-
tion, perhaps resulting in more direct activation of inflamma-
tory processes due to the increased severity of the stressor.
With complete nutritional deprivation, we may however ob-
serve a ceiling effect limiting the total time microglia are ca-
pable of surviving in the absence of external nutrients. A fur-
ther caveat to the study presented is that cell culture media
commonly contains up to 35 mM glucose, a level an order of
magnitude higher than that typically seen in the CNS. Culture
media in our normal glucose condition contained 17.5 mM
glucose, which may still reflect a hyperglycemic condition;
however, in our preliminary experiments, we did not observe
any significant differences in inflammatory release between
17.5 and 1.75 mM glucose and chose to use the former to
maintain consistency with the bulk of previously published
in vitro studies.
The relevance of metabolic contributions to the pathology
of mood disorders has gained interest in recent years, with
several groups investigating bidirectional correlations be-
tween depression and diabetes or metabolic syndrome
[115–117] and in particular correlations between circulating
lipids (triglycerides, very low-, low-, and/or high-density lipo-
proteins) and suicidality [118, 119]. While these are observa-
tional studies of peripheral biomarkers, our data suggests met-
abolic states are capable of affecting microglia and as such
may contribute to disease pathology through convergent ef-
fects on the inflammatory status of the CNS. As the key
regulators of inflammation in the CNS, microglia possess a
unique duality—acting as both a likely contributor to the path-
ophysiology of depressive disorders and as an ideal point of
therapeutic intervention. The deficits present in our under-
standing of the trafficking and metabolism of lipids in microg-
lia, and the potential consequences of dysregulation of lipid
dynamics in microglia may represent an underexplored point
of intervention to influence microglial fate and function in
neurological, neurodegenerative and neuropsychiatric
disorders.
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